JP2000511898A5 - - Google Patents

Download PDF

Info

Publication number
JP2000511898A5
JP2000511898A5 JP1998500616A JP50061698A JP2000511898A5 JP 2000511898 A5 JP2000511898 A5 JP 2000511898A5 JP 1998500616 A JP1998500616 A JP 1998500616A JP 50061698 A JP50061698 A JP 50061698A JP 2000511898 A5 JP2000511898 A5 JP 2000511898A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998500616A
Other languages
English (en)
Japanese (ja)
Other versions
JP5006998B2 (ja
JP2000511898A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/008697 external-priority patent/WO1997046256A1/en
Publication of JP2000511898A publication Critical patent/JP2000511898A/ja
Publication of JP2000511898A5 publication Critical patent/JP2000511898A5/ja
Application granted granted Critical
Publication of JP5006998B2 publication Critical patent/JP5006998B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50061698A 1996-05-23 1997-05-22 Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法 Expired - Lifetime JP5006998B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1817596P 1996-05-23 1996-05-23
US60/018,175 1996-05-23
PCT/US1997/008697 WO1997046256A1 (en) 1996-05-23 1997-05-22 Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012077703A Division JP2012143245A (ja) 1996-05-23 2012-03-29 Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法

Publications (3)

Publication Number Publication Date
JP2000511898A JP2000511898A (ja) 2000-09-12
JP2000511898A5 true JP2000511898A5 (enExample) 2005-01-13
JP5006998B2 JP5006998B2 (ja) 2012-08-22

Family

ID=21786645

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50061698A Expired - Lifetime JP5006998B2 (ja) 1996-05-23 1997-05-22 Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法
JP2012077703A Withdrawn JP2012143245A (ja) 1996-05-23 2012-03-29 Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012077703A Withdrawn JP2012143245A (ja) 1996-05-23 2012-03-29 Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法

Country Status (12)

Country Link
US (4) US6355479B1 (enExample)
EP (1) EP0969865B1 (enExample)
JP (2) JP5006998B2 (enExample)
AT (1) ATE347588T1 (enExample)
AU (1) AU723355B2 (enExample)
CA (1) CA2254975C (enExample)
DE (1) DE69737070T2 (enExample)
DK (1) DK0969865T3 (enExample)
ES (1) ES2278390T3 (enExample)
IL (1) IL126843A (enExample)
PT (1) PT969865E (enExample)
WO (1) WO1997046256A1 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2254975C (en) * 1996-05-23 2008-12-16 The Scripps Research Institute Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
DE69941150D1 (de) 1998-05-11 2009-09-03 Miltenyi Biotec Gmbh Verfahren zur direkten auswahl von antigen-spezifischen t-zellen
US6230662B1 (en) 1998-06-22 2001-05-15 Theresa Miale Animal lift and transport apparatus and method for using the same
EP1104456A1 (en) * 1998-08-10 2001-06-06 Chiron Corporation Engineered antigen-presenting cells expressing an array of antigens and uses thereof
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
JP2002527467A (ja) * 1998-10-20 2002-08-27 サルバトーレ・アルバーニ 抗原特異的ｔ細胞の単離、定量、特徴づけおよび調節方法
US6225443B1 (en) * 1999-05-19 2001-05-01 Wisconsin Alumni Research Foundation Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
US7541429B2 (en) 2000-10-10 2009-06-02 The Board Of Regents Of The University Of Oklahoma Comparative ligand mapping from MHC positive cells
DE10009341A1 (de) * 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
WO2001080833A1 (en) * 2000-04-20 2001-11-01 Salvatore Albani Methods for isolation, quantification, characterization and modulation of antigen-specific t cells
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
WO2002056908A2 (en) * 2001-01-16 2002-07-25 Hildebrand William H Artificial antigen-presenting cells
US7579007B2 (en) * 2001-02-13 2009-08-25 Jdm Technologies, Inc. Production of “biological carriers” for induction of immune responses and inhibition of viral replication
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
DE60226853D1 (de) * 2001-02-20 2008-07-10 Ortho Mcneil Pharm Inc Zelltherapieverfahren für die behandlung von tumoren
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
WO2003057171A2 (en) * 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
ES2282355T3 (es) * 2002-10-11 2007-10-16 Sentoclone Ab Inmunoterapia de cancer.
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
EP1692504A4 (en) * 2003-11-03 2007-06-27 Beckman Coulter Inc METHODS BASED ON DETECTION SOLUTIONS OF PEPTIDES FIXING AT THE MHC
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
US7678572B2 (en) 2004-02-26 2010-03-16 Immunovative Therapies, Ltd. Methods for preparing T-cells for cell therapy
EP1766393A4 (en) * 2004-05-07 2008-06-18 Beckman Coulter Inc MHC-BRIDGE SYSTEM FOR DETECTION OF THE CTL-MEDIATED LYSE OF ANTIGEN-PRESENTING CELLS
ES2653570T3 (es) 2004-05-27 2018-02-07 The Trustees Of The University Of Pennsylvania Células presentadoras de antígeno artificiales novedosas y usos de las mismas
EP2226332A1 (en) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
EP1712615A1 (en) * 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
WO2006138449A2 (en) * 2005-06-16 2006-12-28 The Wistar Institute Method for identifying a mhc class ii-dependent tumor-associated t helper cell antigen
US8206702B2 (en) 2005-12-21 2012-06-26 Sentoclone International Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
WO2007071410A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating urinary bladder cancer
AU2006328945B2 (en) 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
CN101351546B (zh) 2005-12-21 2013-05-29 江苏太瑞生诺生物医药科技有限公司 治疗播散性癌症的方法
KR20080098066A (ko) 2006-03-01 2008-11-06 얀센 파마슈티카 엔.브이. 림프구 제거제를 ｃｔｌ 및 사이토카인과 결합한 암 치료
JP5543207B2 (ja) 2006-10-04 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用
NZ720288A (en) * 2006-12-27 2020-02-28 Harvard College Compositions and methods for the treatment of infections and tumors
US20120034155A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CN102282265B (zh) * 2008-11-28 2020-07-24 埃默里大学 用于治疗传染病和肿瘤的方法
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
EP2404618A1 (en) 2010-07-07 2012-01-11 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Immunomodulatory protein constructs with a helical polymeric backbone.
US20130071437A1 (en) * 2010-08-06 2013-03-21 Canine-Lab.Inc. Immunological function enhancing agent
BR112013028285A2 (pt) 2011-05-03 2017-01-10 Immunovative Therapies Ltd indução de il-12 usando imunoterapia
CA2838041C (en) 2011-05-03 2018-09-25 Immunovative Therapies, Ltd. Methods for handling biological drugs containing living cells
WO2013163171A1 (en) 2012-04-24 2013-10-31 Kaufman Dan S Method for developing natural killer cells from stem cells
KR102238226B1 (ko) 2013-05-14 2021-04-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
CN113648406A (zh) 2013-12-16 2021-11-16 美利坚合众国, 由健康及人类服务部部长代表 通过使用vlp复制子投递ii类mhc抗原的癌症免疫疗法
KR102375998B1 (ko) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
WO2015148960A1 (en) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
KR20160145802A (ko) 2014-04-23 2016-12-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
CA2945393C (en) 2014-04-24 2021-03-23 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
EP3215534B1 (en) 2014-11-05 2020-04-15 Board of Regents, The University of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
HK1243441A1 (zh) 2014-11-05 2018-07-13 Board Of Regents, The University Of Texas System 基因修饰的免疫效应细胞和用於扩增免疫效应细胞的工程化细胞
FR3031519B1 (fr) 2015-01-14 2016-12-30 Arkema France Composition a base de terpolymere electroactif
CA2979493A1 (en) * 2015-03-16 2016-09-22 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
US11787848B2 (en) 2016-06-08 2023-10-17 Precigen, Inc. CD33 specific chimeric antigen receptors
AU2017301887A1 (en) 2016-07-29 2019-02-07 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-CD19 antibodies
EP3538112A4 (en) 2016-11-09 2020-09-02 Musc Foundation for Research Development CD38-NAD + REGULATED METABOLIC AXIS IN ANTITUMOR IMMUNOTHERAPY
KR20240128814A (ko) 2017-01-10 2024-08-27 프레시전 인코포레이티드 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
US11285196B2 (en) 2017-03-13 2022-03-29 Eslam Abbas Baseuny Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof
MX2019011897A (es) 2017-04-18 2019-11-28 Fujifilm Cellular Dynamics Inc Celulas efectoras inmunitarias especificas de antigenos.
AU2018281316B2 (en) 2017-06-07 2024-05-30 Precigen, Inc. Expression of novel cell tags
US12178787B2 (en) 2017-10-12 2024-12-31 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
AU2019386140A1 (en) 2018-11-28 2021-06-24 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
CN113316455A (zh) 2018-11-29 2021-08-27 得克萨斯大学体系董事会 用于离体扩增自然杀伤细胞的方法及其用途
AU2020379848A1 (en) 2019-11-06 2022-05-19 Baylor College Of Medicine Method for producing cytotoxic effector memory T cells for T-cell treatment of cancer
US20230079539A1 (en) 2020-02-10 2023-03-16 Board Of Regents, The University Of Texas System Methods for rapid cloning and expression of hla class i cells
JP2023537558A (ja) 2020-05-27 2023-09-04 アンチオン バイオサイエンシーズ エスアー 目的の抗原にｃａｒ ｔ細胞をリダイレクトするためのアダプター分子
US12275766B2 (en) 2020-12-23 2025-04-15 Janssen Biotech, Inc. Neoantigen peptide mimics
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242687A (en) 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
JP2683461B2 (ja) * 1991-07-05 1997-11-26 住友電気工業株式会社 光ファイバケーブルの製造方法
US5583031A (en) * 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
US5314813A (en) 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
WO1996012009A2 (en) * 1994-10-14 1996-04-25 Tykocinski Mark L Methods for engineering antigen-presenting cells
CA2254975C (en) * 1996-05-23 2008-12-16 The Scripps Research Institute Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2001509146A5 (enExample)
JP2000501771A5 (enExample)
JP2000501018A5 (enExample)
JP2001502058A5 (enExample)
JP2000507117A5 (enExample)
JP2000501324A5 (enExample)
JP2000511898A5 (enExample)
JP2000515062A5 (enExample)
JP2001504980A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2000501338A5 (enExample)
JP2000500874A5 (enExample)
JP2000502425A5 (enExample)
JP2000502485A5 (enExample)
JP2001500092A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2001502415A5 (enExample)
JP2000501876A5 (enExample)
JP2000504666A5 (enExample)
JP2000514124A5 (enExample)